Published in Cancer Res on January 12, 2010
Tackling the cancer stem cells - what challenges do they pose? Nat Rev Drug Discov (2014) 2.55
Aldehyde dehydrogenase activity selects for lung adenocarcinoma stem cells dependent on notch signaling. Cancer Res (2010) 2.54
Targeting CXCR1/2 significantly reduces breast cancer stem cell activity and increases the efficacy of inhibiting HER2 via HER2-dependent and -independent mechanisms. Clin Cancer Res (2012) 2.24
Targeting Notch, Hedgehog, and Wnt pathways in cancer stem cells: clinical update. Nat Rev Clin Oncol (2015) 2.02
Critical research gaps and translational priorities for the successful prevention and treatment of breast cancer. Breast Cancer Res (2013) 1.92
Understanding and targeting cancer stem cells: therapeutic implications and challenges. Acta Pharmacol Sin (2013) 1.83
Targeting breast cancer stem cells. Mol Oncol (2010) 1.72
From fly wings to targeted cancer therapies: a centennial for notch signaling. Cancer Cell (2014) 1.70
Notch inhibitors for cancer treatment. Pharmacol Ther (2013) 1.55
Suppression of apoptosis inhibitor c-FLIP selectively eliminates breast cancer stem cell activity in response to the anti-cancer agent, TRAIL. Breast Cancer Res (2011) 1.54
Notch activation inhibits AML growth and survival: a potential therapeutic approach. J Exp Med (2013) 1.54
The double-edged sword of Notch signaling in cancer. Semin Cell Dev Biol (2012) 1.53
Role of Notch and its oncogenic signaling crosstalk in breast cancer. Biochim Biophys Acta (2010) 1.50
The Notch signaling pathway as a mediator of tumor survival. Carcinogenesis (2013) 1.50
Regulation of the embryonic morphogen Nodal by Notch4 facilitates manifestation of the aggressive melanoma phenotype. Cancer Res (2010) 1.49
ZNF703 gene amplification at 8p12 specifies luminal B breast cancer. EMBO Mol Med (2011) 1.47
Lunatic fringe deficiency cooperates with the Met/Caveolin gene amplicon to induce basal-like breast cancer. Cancer Cell (2012) 1.44
Doxycycline down-regulates DNA-PK and radiosensitizes tumor initiating cells: Implications for more effective radiation therapy. Oncotarget (2015) 1.39
High mitochondrial mass identifies a sub-population of stem-like cancer cells that are chemo-resistant. Oncotarget (2015) 1.27
Notch signaling: targeting cancer stem cells and epithelial-to-mesenchymal transition. Onco Targets Ther (2013) 1.23
Targeting both Notch and ErbB-2 signalling pathways is required for prevention of ErbB-2-positive breast tumour recurrence. Br J Cancer (2011) 1.23
Wnt pathway activity in breast cancer sub-types and stem-like cells. PLoS One (2013) 1.21
Gamma secretase inhibitors of Notch signaling. Onco Targets Ther (2013) 1.21
Preclinical and clinical studies of gamma secretase inhibitors with docetaxel on human breast tumors. Clin Cancer Res (2013) 1.20
A rare population of CD24(+)ITGB4(+)Notch(hi) cells drives tumor propagation in NSCLC and requires Notch3 for self-renewal. Cancer Cell (2013) 1.19
Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease. Nat Rev Clin Oncol (2016) 1.18
Epithelial-to-mesenchymal transition (EMT) confers primary resistance to trastuzumab (Herceptin). Cell Cycle (2012) 1.18
Notch1 inhibition alters the CD44hi/CD24lo population and reduces the formation of brain metastases from breast cancer. Mol Cancer Res (2011) 1.18
Pathways to breast cancer recurrence. ISRN Oncol (2013) 1.15
The notch ligand JAGGED1 as a target for anti-tumor therapy. Front Oncol (2014) 1.11
Repression of mammary stem/progenitor cells by p53 is mediated by Notch and separable from apoptotic activity. Stem Cells (2011) 1.10
Nicastrin regulates breast cancer stem cell properties and tumor growth in vitro and in vivo. Proc Natl Acad Sci U S A (2012) 1.09
Regulation of cell growth by Notch signaling and its differential requirement in normal vs. tumor-forming stem cells in Drosophila. Genes Dev (2011) 1.08
Triple negative breast cancer initiating cell subsets differ in functional and molecular characteristics and in γ-secretase inhibitor drug responses. EMBO Mol Med (2013) 1.04
An improved syngeneic orthotopic murine model of human breast cancer progression. Breast Cancer Res Treat (2014) 1.03
NOTCH1 inhibition in vivo results in mammary tumor regression and reduced mammary tumorsphere-forming activity in vitro. Breast Cancer Res (2012) 1.02
Oestrogen increases the activity of oestrogen receptor negative breast cancer stem cells through paracrine EGFR and Notch signalling. Breast Cancer Res (2013) 1.02
Cancer stem-like cells in Epstein-Barr virus-associated nasopharyngeal carcinoma. Chin J Cancer (2014) 1.02
Cripto-1 as a novel therapeutic target for triple negative breast cancer. Oncotarget (2015) 1.01
Withaferin A causes activation of Notch2 and Notch4 in human breast cancer cells. Breast Cancer Res Treat (2012) 1.01
A differential role for CXCR4 in the regulation of normal versus malignant breast stem cell activity. Oncotarget (2014) 1.00
Notch signaling in lung cancer. Expert Rev Anticancer Ther (2011) 1.00
NOTCH-1 and NOTCH-4 are novel gene targets of PEA3 in breast cancer: novel therapeutic implications. Breast Cancer Res (2011) 0.99
Lack of correlation of stem cell markers in breast cancer stem cells. Br J Cancer (2014) 0.97
Notch signaling as a therapeutic target for breast cancer treatment? Breast Cancer Res (2011) 0.97
NOTCH-induced aldehyde dehydrogenase 1A1 deacetylation promotes breast cancer stem cells. J Clin Invest (2014) 0.97
c-Myc dependent expression of pro-apoptotic Bim renders HER2-overexpressing breast cancer cells dependent on anti-apoptotic Mcl-1. Mol Cancer (2011) 0.97
C8orf4 negatively regulates self-renewal of liver cancer stem cells via suppression of NOTCH2 signalling. Nat Commun (2015) 0.97
Breast cancer stem cells. Front Physiol (2013) 0.95
Targeted inhibition of Hsp90 by ganetespib is effective across a broad spectrum of breast cancer subtypes. Invest New Drugs (2013) 0.94
Prolyl-isomerase Pin1 controls normal and cancer stem cells of the breast. EMBO Mol Med (2013) 0.94
Progesterone regulation of stem and progenitor cells in normal and malignant breast. Mol Cell Endocrinol (2011) 0.93
Molecular characterization and targeted therapeutic approaches in breast cancer. Breast Cancer Res (2015) 0.93
Pre-clinical studies of Notch signaling inhibitor RO4929097 in inflammatory breast cancer cells. Breast Cancer Res Treat (2012) 0.93
Novel clinical therapeutics targeting the epithelial to mesenchymal transition. Clin Transl Med (2014) 0.93
The role of cancer stem cells in breast cancer initiation and progression: potential cancer stem cell-directed therapies. Oncologist (2012) 0.92
Ceramide glycosylation by glucosylceramide synthase selectively maintains the properties of breast cancer stem cells. J Biol Chem (2012) 0.92
Luteolin is a novel p90 ribosomal S6 kinase (RSK) inhibitor that suppresses Notch4 signaling by blocking the activation of Y-box binding protein-1 (YB-1). Oncotarget (2013) 0.91
Crosstalk between PKCα and Notch-4 in endocrine-resistant breast cancer cells. Oncogenesis (2013) 0.91
Shared signaling pathways in normal and breast cancer stem cells. J Carcinog (2011) 0.91
Therapeutic strategies targeting cancer stem cells. Cancer Biol Ther (2013) 0.91
Wound healing and cancer stem cells: inflammation as a driver of treatment resistance in breast cancer. Cancer Growth Metastasis (2015) 0.90
Multiple roles of COUP-TFII in cancer initiation and progression. J Mol Endocrinol (2012) 0.89
The emerging importance of α-L-fucose in human breast cancer: a review. Am J Transl Res (2011) 0.89
Anti-estrogen Resistance in Human Breast Tumors Is Driven by JAG1-NOTCH4-Dependent Cancer Stem Cell Activity. Cell Rep (2015) 0.89
Notch2 activation by benzyl isothiocyanate impedes its inhibitory effect on breast cancer cell migration. Breast Cancer Res Treat (2012) 0.88
Inhibition of redox/Fyn/c-Cbl pathway function by Cdc42 controls tumour initiation capacity and tamoxifen sensitivity in basal-like breast cancer cells. EMBO Mol Med (2013) 0.88
Runx2 is a novel regulator of mammary epithelial cell fate in development and breast cancer. Cancer Res (2014) 0.87
Cancer stem cells: potential target for bioactive food components. J Nutr Biochem (2012) 0.86
Notch signals in the endothelium and cancer "stem-like" cells: opportunities for cancer therapy. Vasc Cell (2012) 0.86
An integrated genomic approach identifies that the PI3K/AKT/FOXO pathway is involved in breast cancer tumor initiation. Oncotarget (2016) 0.86
The role of Adams in Notch signaling. Adv Exp Med Biol (2012) 0.86
Manic fringe promotes a claudin-low breast cancer phenotype through notch-mediated PIK3CG induction. Cancer Res (2015) 0.86
Targeting Met and Notch in the Lfng-deficient, Met-amplified triple-negative breast cancer. Cancer Biol Ther (2014) 0.86
Combined inhibition of ErbB1/2 and Notch receptors effectively targets breast ductal carcinoma in situ (DCIS) stem/progenitor cell activity regardless of ErbB2 status. PLoS One (2013) 0.85
Targeting breast cancer-initiating/stem cells with melanoma differentiation-associated gene-7/interleukin-24. Int J Cancer (2013) 0.85
BRCA1 is a key regulator of breast differentiation through activation of Notch signalling with implications for anti-endocrine treatment of breast cancers. Nucleic Acids Res (2013) 0.84
Heterogeneity of breast cancer stem cells as evidenced with Notch-dependent and Notch-independent populations. Cancer Med (2012) 0.84
ROCK1 inhibition promotes the self-renewal of a novel mouse mammary cancer stem cell. Stem Cells (2013) 0.84
Common stemness regulators of embryonic and cancer stem cells. World J Stem Cells (2015) 0.84
γ-Secretase inhibition promotes cell death, Noxa upregulation, and sensitization to BH3 mimetic ABT-737 in human breast cancer cells. Breast Cancer Res (2012) 0.83
Function of Integrin-Linked Kinase in Modulating the Stemness of IL-6-Abundant Breast Cancer Cells by Regulating γ-Secretase-Mediated Notch1 Activation in Caveolae. Neoplasia (2015) 0.83
Dickkopf1 regulates fate decision and drives breast cancer stem cells to differentiation: an experimentally supported mathematical model. PLoS One (2011) 0.83
Microarray-based analysis of microRNA expression in breast cancer stem cells. J Exp Clin Cancer Res (2010) 0.83
Targeting Notch to overcome radiation resistance. Oncotarget (2016) 0.82
Gene Expression Analysis Reveals Distinct Pathways of Resistance to Bevacizumab in Xenograft Models of Human ER-Positive Breast Cancer. J Cancer (2014) 0.82
Targeted therapy against cancer stem cells. Oncol Lett (2015) 0.82
Cancer stem cell markers in breast neoplasias: their relevance and distribution in distinct molecular subtypes. Virchows Arch (2012) 0.82
Profiling immunohistochemical expression of NOTCH1-3, JAGGED1, cMET, and phospho-MAPK in 100 carcinomas of unknown primary. Clin Exp Metastasis (2012) 0.82
Biological and clinical significance of cancer stem cell plasticity. Clin Transl Med (2014) 0.82
Therapies targeting cancer stem cells: Current trends and future challenges. World J Stem Cells (2015) 0.82
Identification of Distinct Breast Cancer Stem Cell Populations Based on Single-Cell Analyses of Functionally Enriched Stem and Progenitor Pools. Stem Cell Reports (2016) 0.81
Combining Notch inhibition with current therapies for breast cancer treatment. Ther Adv Med Oncol (2013) 0.81
Identifying and targeting tumor-initiating cells in the treatment of breast cancer. Endocr Relat Cancer (2015) 0.81
Cisplatin selects for stem-like cells in osteosarcoma by activating Notch signaling. Oncotarget (2016) 0.80
Notch signaling: mediator and therapeutic target of bone metastasis. Bonekey Rep (2012) 0.80
Γ-secretase components as predictors of breast cancer outcome. PLoS One (2013) 0.80
HES1-mediated inhibition of Notch1 signaling by a Gemini vitamin D analog leads to decreased CD44(+)/CD24(-/low) tumor-initiating subpopulation in basal-like breast cancer. J Steroid Biochem Mol Biol (2014) 0.80
Mammary cancer chemoprevention by withaferin A is accompanied by in vivo suppression of self-renewal of cancer stem cells. Cancer Prev Res (Phila) (2014) 0.80
Targeting cancer stem cells in solid tumors by vitamin D. J Steroid Biochem Mol Biol (2014) 0.80
Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A (2003) 59.17
Identification of human brain tumour initiating cells. Nature (2004) 38.87
Identification and expansion of human colon-cancer-initiating cells. Nature (2006) 24.44
ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell (2007) 22.89
In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells. Genes Dev (2003) 20.77
Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res (2005) 13.89
Molecular definition of breast tumor heterogeneity. Cancer Cell (2007) 12.67
Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J Natl Cancer Inst (2008) 11.93
Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor cell properties. Cancer Res (2005) 11.52
Notch/gamma-secretase inhibition turns proliferative cells in intestinal crypts and adenomas into goblet cells. Nature (2005) 11.49
The response of CD24(-/low)/CD44+ breast cancer-initiating cells to radiation. J Natl Cancer Inst (2006) 10.06
Human breast cancer cell lines contain stem-like cells that self-renew, give rise to phenotypically diverse progeny and survive chemotherapy. Breast Cancer Res (2008) 7.65
Role of Notch signaling in cell-fate determination of human mammary stem/progenitor cells. Breast Cancer Res (2004) 5.60
CD24 staining of mouse mammary gland cells defines luminal epithelial, myoepithelial/basal and non-epithelial cells. Breast Cancer Res (2005) 4.79
High-level coexpression of JAG1 and NOTCH1 is observed in human breast cancer and is associated with poor overall survival. Cancer Res (2005) 4.61
Notch signaling regulates mammary stem cell function and luminal cell-fate commitment. Cell Stem Cell (2008) 4.45
Activation of Notch-1 signaling maintains the neoplastic phenotype in human Ras-transformed cells. Nat Med (2002) 4.04
Aberrant activation of notch signaling in human breast cancer. Cancer Res (2006) 3.92
Transcriptome analysis of the normal human mammary cell commitment and differentiation process. Cell Stem Cell (2008) 3.87
Loss of negative regulation by Numb over Notch is relevant to human breast carcinogenesis. J Cell Biol (2004) 3.87
A putative human breast stem cell population is enriched for steroid receptor-positive cells. Dev Biol (2005) 3.19
Novel cell culture technique for primary ductal carcinoma in situ: role of Notch and epidermal growth factor receptor signaling pathways. J Natl Cancer Inst (2007) 2.75
Mammary tumorigenesis in feral mice: identification of a new int locus in mouse mammary tumor virus (Czech II)-induced mammary tumors. J Virol (1987) 2.51
Effects of a gamma-secretase inhibitor in a randomized study of patients with Alzheimer disease. Neurology (2006) 2.21
Cross-talk between notch and the estrogen receptor in breast cancer suggests novel therapeutic approaches. Cancer Res (2008) 2.19
High-level JAG1 mRNA and protein predict poor outcome in breast cancer. Mod Pathol (2007) 1.94
The canonical Notch/RBP-J signaling pathway controls the balance of cell lineages in mammary epithelium during pregnancy. Dev Biol (2006) 1.80
ErbB-2 inhibition activates Notch-1 and sensitizes breast cancer cells to a gamma-secretase inhibitor. Oncogene (2008) 1.69
JAG1 expression is associated with a basal phenotype and recurrence in lymph node-negative breast cancer. Breast Cancer Res Treat (2007) 1.69
Normal and leukemic human stem cells assayed in SCID mice. Semin Immunol (1996) 1.54
Studies to investigate the in vivo therapeutic window of the gamma-secretase inhibitor N2-[(2S)-2-(3,5-difluorophenyl)-2-hydroxyethanoyl]-N1-[(7S)-5-methyl-6-oxo-6,7-dihydro-5H-dibenzo[b,d]azepin-7-yl]-L-alaninamide (LY411,575) in the CRND8 mouse. J Pharmacol Exp Ther (2006) 1.36
Identification of a novel NOTCH-4/INT-3 RNA species encoding an activated gene product in certain human tumor cell lines. Oncogene (2000) 1.23
Prolactin receptor antagonism reduces the clonogenic capacity of breast cancer cells and potentiates doxorubicin and paclitaxel cytotoxicity. Breast Cancer Res (2008) 1.14
Effects of 4-hydroxytamoxifen and a novel pure antioestrogen (ICI 182780) on the clonogenic growth of human breast cancer cells in vitro. Br J Cancer (1994) 0.96
Effect of tamoxifen and radiotherapy in women with locally excised ductal carcinoma in situ: long-term results from the UK/ANZ DCIS trial. Lancet Oncol (2010) 3.27
Novel cell culture technique for primary ductal carcinoma in situ: role of Notch and epidermal growth factor receptor signaling pathways. J Natl Cancer Inst (2007) 2.75
Mammary stem cells and breast cancer--role of Notch signalling. Stem Cell Rev (2007) 2.62
Targeting CXCR1/2 significantly reduces breast cancer stem cell activity and increases the efficacy of inhibiting HER2 via HER2-dependent and -independent mechanisms. Clin Cancer Res (2012) 2.24
A detailed mammosphere assay protocol for the quantification of breast stem cell activity. J Mammary Gland Biol Neoplasia (2012) 1.98
Critical research gaps and translational priorities for the successful prevention and treatment of breast cancer. Breast Cancer Res (2013) 1.92
Safety and efficacy of tibolone in breast-cancer patients with vasomotor symptoms: a double-blind, randomised, non-inferiority trial. Lancet Oncol (2009) 1.90
The centrosomal kinase Nek2 displays elevated levels of protein expression in human breast cancer. Cancer Res (2004) 1.72
Wnt proteins induce dishevelled phosphorylation via an LRP5/6- independent mechanism, irrespective of their ability to stabilize beta-catenin. Mol Cell Biol (2004) 1.68
The mammary gland "side population": a putative stem/progenitor cell marker? J Mammary Gland Biol Neoplasia (2005) 1.57
Idiopathic granulomatous mastitis: a 25-year experience. J Am Coll Surg (2007) 1.52
Absence of HER4 expression predicts recurrence of ductal carcinoma in situ of the breast. Clin Cancer Res (2005) 1.49
Steroid receptors and cell cycle in normal mammary epithelium. J Mammary Gland Biol Neoplasia (2004) 1.47
Ductal carcinoma in situ of the breast. BMJ (2012) 1.47
The removal of multiplicative, systematic bias allows integration of breast cancer gene expression datasets - improving meta-analysis and prediction of prognosis. BMC Med Genomics (2008) 1.41
Notch activation induces Akt signaling via an autocrine loop to prevent apoptosis in breast epithelial cells. Cancer Res (2009) 1.40
Origins of breast cancer subtypes and therapeutic implications. Nat Clin Pract Oncol (2007) 1.36
Wnt pathway activity in breast cancer sub-types and stem-like cells. PLoS One (2013) 1.21
Comprehensive CYP2D6 genotype and adherence affect outcome in breast cancer patients treated with tamoxifen monotherapy. Breast Cancer Res Treat (2010) 1.18
The mitogenic action of insulin-like growth factor I in normal human mammary epithelial cells requires the epidermal growth factor receptor tyrosine kinase. J Biol Chem (2003) 1.18
Recent advances reveal IL-8 signaling as a potential key to targeting breast cancer stem cells. Breast Cancer Res (2013) 1.16
Prolactin receptor antagonism reduces the clonogenic capacity of breast cancer cells and potentiates doxorubicin and paclitaxel cytotoxicity. Breast Cancer Res (2008) 1.14
Risk determination and prevention of breast cancer. Breast Cancer Res (2014) 1.11
Targeting inhibitor of apoptosis proteins in combination with ErbB antagonists in breast cancer. Breast Cancer Res (2009) 1.10
The embryonic transcription cofactor LBH is a direct target of the Wnt signaling pathway in epithelial development and in aggressive basal subtype breast cancers. Mol Cell Biol (2010) 1.10
Effect of a farnesyl transferase inhibitor (R115777) on ductal carcinoma in situ of the breast in a human xenograft model and on breast and ovarian cancer cell growth in vitro and in vivo. Breast Cancer Res (2006) 1.09
Breast cancer stem cells: something out of notching? Cancer Res (2010) 1.05
Notch signaling through Jagged-1 is necessary to initiate chondrogenesis in human bone marrow stromal cells but must be switched off to complete chondrogenesis. Stem Cells (2008) 1.05
Oestrogen increases the activity of oestrogen receptor negative breast cancer stem cells through paracrine EGFR and Notch signalling. Breast Cancer Res (2013) 1.02
Resistance to endocrine therapy: are breast cancer stem cells the culprits? J Mammary Gland Biol Neoplasia (2009) 1.02
A differential role for CXCR4 in the regulation of normal versus malignant breast stem cell activity. Oncotarget (2014) 1.00
Stem cells in breast tumours: are they ready for the clinic? Eur J Cancer (2012) 1.00
Disruption of a Quorum Sensing mechanism triggers tumorigenesis: a simple discrete model corroborated by experiments in mammary cancer stem cells. Biol Direct (2010) 1.00
Human breast epithelial stem cells and their regulation. J Pathol (2006) 1.00
P-cadherin is coexpressed with CD44 and CD49f and mediates stem cell properties in basal-like breast cancer. Stem Cells (2012) 0.99
High-throughput genomic technology in research and clinical management of breast cancer. Exploiting the potential of gene expression profiling: is it ready for the clinic? Breast Cancer Res (2006) 0.98
Enrichment of human osteosarcoma stem cells based on hTERT transcriptional activity. Oncotarget (2013) 0.97
Small-molecule inhibitors of the MDM2-p53 protein-protein interaction based on an isoindolinone scaffold. J Med Chem (2006) 0.96
Contrasting hypoxic effects on breast cancer stem cell hierarchy is dependent on ER-α status. Cancer Res (2012) 0.96
Biomarkers of dietary energy restriction in women at increased risk of breast cancer. Cancer Prev Res (Phila) (2009) 0.96
Breast cancer: current and future endocrine therapies. Mol Cell Endocrinol (2013) 0.95
Breast cancer stem cells and their role in resistance to endocrine therapy. Horm Cancer (2011) 0.95
Molecular markers and therapeutic targets in ductal carcinoma in situ. Microsc Res Tech (2002) 0.91
Targeting treatment-resistant breast cancer stem cells with FKBPL and its peptide derivative, AD-01, via the CD44 pathway. Clin Cancer Res (2013) 0.90
Cell cycle regulators cyclin D1 and CDK4/6 have estrogen receptor-dependent divergent functions in breast cancer migration and stem cell-like activity. Cell Cycle (2013) 0.89
Facilitating reproductive choices: the impact of health services on the experiences of young women with breast cancer. Psychooncology (2010) 0.88
P-cadherin signals through the laminin receptor α6β4 integrin to induce stem cell and invasive properties in basal-like breast cancer cells. Oncotarget (2014) 0.87
It's all in the details: methods in breast development and cancer. Breast Cancer Res (2009) 0.87
Effect of epidermal growth factor receptor tyrosine kinase inhibition on epithelial proliferation in normal and premalignant breast. Cancer Res (2002) 0.86
New approaches to the endocrine prevention and treatment of breast cancer. Cancer Chemother Pharmacol (2003) 0.86
Isoindolinone-based inhibitors of the MDM2-p53 protein-protein interaction. Bioorg Med Chem Lett (2005) 0.85
Combined inhibition of ErbB1/2 and Notch receptors effectively targets breast ductal carcinoma in situ (DCIS) stem/progenitor cell activity regardless of ErbB2 status. PLoS One (2013) 0.85
Focal adhesion kinase and Wnt signaling regulate human ductal carcinoma in situ stem cell activity and response to radiotherapy. Stem Cells (2015) 0.84
Dickkopf1 regulates fate decision and drives breast cancer stem cells to differentiation: an experimentally supported mathematical model. PLoS One (2011) 0.83
Are stem-like cells responsible for resistance to therapy in breast cancer? Breast Dis (2008) 0.82
Targeting IL-8 signalling to inhibit breast cancer stem cell activity. Expert Opin Ther Targets (2013) 0.82
Re: Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst (2009) 0.81
Combining Notch inhibition with current therapies for breast cancer treatment. Ther Adv Med Oncol (2013) 0.81
Short-term biologic response to withdrawal of hormone replacement therapy in patients with invasive breast carcinoma. Cancer (2003) 0.80
Avoidance of CYP2D6 inhibitors in patients receiving tamoxifen. J Clin Oncol (2010) 0.80
Response and resistance to the endocrine prevention of breast cancer. Adv Exp Med Biol (2008) 0.79
Mechanisms of Disease: prediction and prevention of breast cancer--cellular and molecular interactions. Nat Clin Pract Oncol (2005) 0.79
Multifunctionalized iron oxide nanoparticles for selective drug delivery to CD44-positive cancer cells. Nanotechnology (2016) 0.78
Normal breast tissue implanted into athymic nude mice identifies biomarkers of the effects of human pregnancy levels of estrogen. Cancer Prev Res (Phila) (2009) 0.78
Lack of caveolin-1 (P132L) somatic mutations in breast cancer. Breast Cancer Res Treat (2012) 0.78
To switch or not to switch: should the updated Intergroup Exemestane Study alter our decision? Expert Rev Anticancer Ther (2008) 0.77
17β-estradiol regulates giant vesicle formation via estrogen receptor-alpha in human breast cancer cells. Oncotarget (2014) 0.77
Optimising bone health in survivors of breast cancer. Lancet Oncol (2007) 0.76
‘The charmingest place’: non-coding RNA, lineage tracing, tumor heterogeneity, metastasis and metabolism--new methods in mammary gland development and cancer: the fifth ENBDC Workshop. Breast Cancer Res (2013) 0.75
Do early premalignant changes in normal breast epithelial cells predict cancer development? Breast Cancer Res (2004) 0.75